This article was originally published in The Tan Sheet
An FDA letter to Lidtke Technologies notes the product name "includes a recognizable root of a disease name." Product claims stating DiabeStat is "for the lowering of peak postprandial blood glucose levels...among individuals with elevated levels," suggest the product is intended to be used as a drug, according to FDA...
You may also be interested in...
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.
Dutch foot-care specialists TheOTCLab launches what it claims to be the world's first fungal nail plaster.